RXRX241206C2000
- 5.33
- 0.000.00%
Recursion Pharmaceuticals Newsroom
Jim Cramer on Recursion Pharmaceuticals, Inc. (RXRX): 'It Is Worthwhile Speculation'
10 Health Care Stocks Whale Activity In Today's Session
Recursion Pharmaceuticals CFO Ben Taylor to Join Exscientia
Recursion Pharmaceuticals Call Volume Above Normal and Directionally Bullish
Recursion Pharmaceuticals (RXRX) Bold Acquisition Makes It a Leader in AI Drug Discovery
Recursion Announces First Patient Dosed In Phase 1/2 Clinical Study Of REC-1245, A RBM39 Degrader For Biomarker-Enriched Solid Tumors And Lymphoma
Express News | Recursion Announces First Patient Dosed in Phase 1/2 Clinical Study of REC-1245, a Potential First-in-Class, Rbm39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
Follow Nvidia's Lead in Investing in Small-Cap AI Stocks
Nvidia Bought 6 Artificial Intelligence (AI) Stocks, but This 1 Has Soared the Most
Trending Industry Today: Recursion Pharmaceuticals Leads Gains In NVIDIA Portfolio Stocks
XPeng, NovoCure, Merus, Gap And Other Big Stocks Moving Higher On Monday
Express News | Top 10 Trending Stocks On WallStreetBets As Of December 2, 2024 (Via Swaggy Stocks)
(RXRX) - Analyzing Recursion Pharmaceuticals's Short Interest
Jim Cramer: Reddit Is 'Fabulous,' Dow Is A 'Tough' One
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Recursion Pharmaceuticals (RXRX) and AN2 Therapeutics, Inc. (ANTX)
BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $12
Hold Rating Recommended for Recursion Pharmaceuticals Post-Merger With Exscientia: Upside Potential Amidst Clinical Uncertainties
KeyBanc Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Maintains Target Price $12
Cathie Wood's ARK Investment Buys 383K Shares of Recursion Pharmaceuticals Today